Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today a poster presentation on the safety and efficacy of PRV111 in patients with...

BIO International Convention 2021

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year due to COVID-19, Bio International 2021 was informative and enjoyable. The company connected with potential investors and industry partners in discussing their...

BIO International Convention

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute (NIDCR) in Philadelphia.

Contact Us
close slider

Contact Us